294 related articles for article (PubMed ID: 24505496)
1. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.
Gasparini P; Fassan M; Cascione L; Guler G; Balci S; Irkkan C; Paisie C; Lovat F; Morrison C; Zhang J; Scarpa A; Croce CM; Shapiro CL; Huebner K
PLoS One; 2014; 9(2):e88525. PubMed ID: 24505496
[TBL] [Abstract][Full Text] [Related]
2. High Expression of CCR7 Predicts Lymph Node Metastasis and Good Prognosis in Triple Negative Breast Cancer.
Li X; Sun S; Li N; Gao J; Yu J; Zhao J; Li M; Zhao Z
Cell Physiol Biochem; 2017; 43(2):531-539. PubMed ID: 28930757
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
5. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.
Thike AA; Yong-Zheng Chong L; Cheok PY; Li HH; Wai-Cheong Yip G; Huat Bay B; Tse GM; Iqbal J; Tan PH
Mod Pathol; 2014 Mar; 27(3):352-60. PubMed ID: 23929266
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
7. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
[TBL] [Abstract][Full Text] [Related]
8. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
9. Prognostic markers in triple-negative breast cancer.
Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
[TBL] [Abstract][Full Text] [Related]
10. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
11. Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray.
Guo J; Gong G; Zhang B
Tumour Biol; 2017 Jul; 39(7):1010428317713392. PubMed ID: 28671019
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer.
Avery-Kiejda KA; Braye SG; Mathe A; Forbes JF; Scott RJ
BMC Cancer; 2014 Jan; 14():51. PubMed ID: 24479446
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor status is highly conserved during tumor progression of breast cancer.
Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
[TBL] [Abstract][Full Text] [Related]
14. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
[TBL] [Abstract][Full Text] [Related]
15. Novel genes associated with lymph node metastasis in triple negative breast cancer.
Mathe A; Wong-Brown M; Morten B; Forbes JF; Braye SG; Avery-Kiejda KA; Scott RJ
Sci Rep; 2015 Nov; 5():15832. PubMed ID: 26537449
[TBL] [Abstract][Full Text] [Related]
16. A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes.
Hu T; Zhao G; Liu Y; Long M
Technol Cancer Res Treat; 2021; 20():15330338211027900. PubMed ID: 34159849
[TBL] [Abstract][Full Text] [Related]
17. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
18. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
20. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.
Gazinska P; Grigoriadis A; Brown JP; Millis RR; Mera A; Gillett CE; Holmberg LH; Tutt AN; Pinder SE
Mod Pathol; 2013 Jul; 26(7):955-66. PubMed ID: 23392436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
